-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dipeptidyl peptidase-4 inhibitors, or DPP-4 inhibitors or gliptin drugs, are oral antidiabetic drugs that inhibit dipeptidyl peptidase-4 and are mainly used to treat type 2 diabetes (T2DM).
Diabetes Management FDA
Glucagon raise blood sugar levels, DPP-4 inhibitors may reduce glucagon and reducing hypoglycemic levels.
The principle of hypoglycemic DPP-4 inhibitors is to increase the level of incretin hormone (GLP-1) and GIP that can inhibit the release of glucagon, increase insulin secretion, slow down gastric emptying, and lower blood sugar levels.
For most patients with T2DM, DPP-4 inhibitors should not be used as the initial treatment, but should start with dietary adjustments, weight loss, exercise, and the use of metformin (if there are no contraindications).
Metformin
Parkinson's disease (PD) is the second largest neurodegenerative disease in the world and is characterized by motor retardation, limb stiffness, and tremor.
Parkinson's disease (PD) is the second largest neurodegenerative disease in the world and is characterized by motor retardation, limb stiffness, and tremor.
Studies have shown that those with T2DM have a 32% increased risk of developing a progressively debilitating neurological disease in the later stages.
Studies have shown that those with T2DM have a 32% increased risk of developing a progressively debilitating neurological disease in the later stages.
diagnosis
In PD diabetic patients treated with DPP4 inhibitors in the anterior putamen (2.
In PD diabetic patients treated with DPP4 inhibitors in the anterior putamen (2.
The previous DPP4 inhibitor treatment of blood vessels was still related to the anterior putamen (β = -0.
The linear mixed model showed that the longitudinal increase of levodopa equivalent in the Parkinson's disease diabetes group being treated with a DPP4 inhibitor was slower than the other groups.
The rate of levodopa-induced dyskinesia in the diabetic group previously treated with a DPP4 inhibitor was significantly lower than that in the diabetic group without a DPP4 inhibitor.
These findings indicate that DPP4 inhibitors may have a beneficial effect on the baseline dopamine degeneration of the substantia nigra and long-term exercise results in diabetic Parkinson's disease patients, and may extend its effect to non-diabetic Parkinson's disease patients.
references:
Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease, Brain, Volume 144, Issue 4, April 2021, Pages 1127–1137, https://doi.
Leave a message here
